Hua Medicine
HKEX:2552
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hua Medicine
Research & Development
Hua Medicine
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hua Medicine
HKEX:2552
|
Research & Development
-¥145.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Research & Development
-¥3.4B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Research & Development
-¥6.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Research & Development
-¥323.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Research & Development
-¥1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-18%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Research & Development
-¥1.4B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Hua Medicine
Glance View
Hua Medicine Ltd. provides drug discovery and development services. The company is headquartered in Shanghai, Shanghai and currently employs 146 full-time employees. The company went IPO on 2018-09-14. The firm is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The firm mainly operates its business in the domestic and overseas markets.
See Also
What is Hua Medicine's Research & Development?
Research & Development
-145.3m
CNY
Based on the financial report for Dec 31, 2025, Hua Medicine's Research & Development amounts to -145.3m CNY.
What is Hua Medicine's Research & Development growth rate?
Research & Development CAGR 5Y
8%
Over the last year, the Research & Development growth was 32%. The average annual Research & Development growth rates for Hua Medicine have been -4% over the past three years , 8% over the past five years .
